Author:
Li Huawei,You Jia,Wei Yuanfeng,Zheng Lingnan,Yang Ju,Xu Jingyi,Li Yue,Li Zhaojun,Yang Xi,Yi Cheng
Subject
Complementary and alternative medicine,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine
Reference46 articles.
1. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA;Abou-Alfa;JCO,2022
2. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond;Ai;Adv. Exp. Med. Biol.,2020
3. PD-L1 immunostaining: what pathologists need to know;Akhtar;Diagn. Pathol.,2021
4. Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity;Alspach;CSH Perspect. Biol.,2019
5. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial;Chen;Gut,2018
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献